Clinical Trials Browser

Phase 2 × Neuroectodermal Tumors × CNS × Clear all

Medulloblastoma, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive

NCT03561259 2023-02-16

OPTIMUM

Phase 2 Unknown

60 enrolled

CNS

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

NCT02798406 2021-07-15

CAPTIVE

Phase 2 Completed

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Phase 2 Withdrawn

CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 2 Completed

116 enrolled 8 charts

CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Clinical Trials

Re-MATCH

OPTIMUM

CAPTIVE

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors